Endo-perio Disease - Treatment Outcomes Using Conventional and Hydraulic Calcium Silicate Sealer With or Without LPRF

Launched by KING'S COLLEGE LONDON · Jan 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a specific dental condition known as endodontic-periodontal disease, which affects both the pulp (inner part) of the tooth and the surrounding gums. The researchers want to compare two types of treatments: one using a traditional sealing material and the other using a newer hydraulic calcium silicate sealer, with or without a special preparation called leukocyte platelet-rich fibrin (L-PRF), which may help healing. The goal is to see which treatment leads to better healing and outcomes for patients with this condition.

To participate in this trial, you must be between 18 and 80 years old and have a diagnosis of endodontic-periodontal disease without severe damage to the tooth structure. You should also not have smoked in the last five years and must not have certain dental or health issues that could complicate treatment. If you join the trial, you can expect to receive one of the treatments being studied and will be monitored throughout the process to evaluate how well it works. This study is important because it aims to find better ways to treat a complex dental problem that can lead to tooth loss if not managed properly.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Diagnosis of Endodontic-periodontal disease without root damage in periodontitis patients, Grades I, II, III according to Herrera 2017 classification.
• • Presence of ≥ 1 intrabony defect: interproximal probing pocket depth ≥ 5 mm and ≥ 3mm radiographic intrabony defect, adjacent to single rooted and multi-rooted teeth associated with endodontic-periodontal disease
• • Age: 18-80
• • Non-smokers (zero cigarettes within last 5 years)
• Exclusion Criteria:
• • Endodontic considerations: severely sclerosed canals, external cervical resorption and internal root resorption, perforations, root fracture or cracking, re- RCT, apical surgery and unrestorable teeth
• • Teeth with defects not amenable to regeneration or molar teeth planned for root resection
• • - Periodontal treatment carried out previously to the study site within the last 12 months (excluding not-extensive subgingival debridement as judged by the examining clinician),
• • presence of drug induced gingival overgrowth.
• • Smoking (current or in past 5 years) including e-cigarettes/ vaping
• • History of alcohol or drug abuse,
• • Systemic antibiotic therapy during the 3 months preceding the baseline exam,
• • History of conditions requiring prophylactic antibiotic coverage prior to invasive dental procedures,
• • Anti-inflammatory or anticoagulant therapy during the month preceding the baseline exam,
• • Medical history of diabetes or transmittable diseases,
• • Chronic inflammatory conditions: chronic peptic ulcer, tuberculosis, rheumatoid arthritis, ulcerative colitis, crohn's disease, active hepatitis, inflammatory bowel diseases, irritable bowel syndrome, autoimmune diseases, liver diseases, renal diseases or cancer
• • Medications which alter bone metabolism: hormone replacement therapy, immunosuppressive drugs, corticosteroids, selective serotonin reuptake inhibitors, tumour necrosis factor blockers, IV bisphosphonates, and/or antiresorptive drugs,
• • Self-reported pregnancy or lactation
• • Surgical procedures in the last 6months (any type of surgical procedures)
• • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that according to the investigator may increase the risk associated with trial participation,
• • Poor compliance